Ok not a great scientific output, but a lot of Charisma
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).
Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R.
Ann Rheum Dis. 2010 Mar;69(3):510-6. doi: 10.1136/ard.2009.119016. Epub 2009 Nov 23. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.
Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells.
Hoff H, Knieke K, Cabail Z, Hirseland H, Vratsanos G, Burmester GR, Jorch G, Nadler SG, Bröker B, Hebel K, Brunner-Weinzierl MC.
J Immunol. 2009 May 1;182(9):5342-51. doi: 10.4049/jimmunol.0801624.
Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study.
Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P.
Ann Rheum Dis. 2009 Jul;68(7):1220-7. doi: 10.1136/ard.2008.091876. Epub 2008 Sep 4. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial.
Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, Teng J, Kremer JM.
Ann Rheum Dis. 2008 Aug;67(8):1084-9. Epub 2007 Dec 17.
Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice.
Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, Flynn JL.
Arthritis Rheum. 2007 Aug;56(8):2557-65.
Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects.
Tay L, Leon F, Vratsanos G, Raymond R, Corbo M.
Arthritis Res Ther. 2007;9(2):R38.
Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland LW.
J Rheumatol. 2006 Nov;33(11):2162-6. Epub 2006 Oct 1.
CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus.
Vratsanos GS, Jung S, Park YM, Craft J.
J Exp Med. 2001 Feb 5;193(3):329-37.